间充质干细胞在新型冠状病毒肺炎治疗中的研究现状

Current research in mesenchymal stem cells in the treatment of COVID-19

新型冠状病毒肺炎(COVID-19)由新型冠状病毒(SARS-CoV-2)导致,可发生严重肺部损伤甚至死亡,目前为止仍在全球范围内广泛蔓延。SARS-CoV-2感染依赖于血管紧张素转换酶2(ACE2)和Ⅱ型跨膜丝氨酸蛋白酶,可导致机体免疫紊乱,促发炎症风暴从而损伤靶器官。COVID-19目前尚无特效药物,间充质干细胞(MSCs)具有组织修复和免疫调节等功能,而且在流感病毒相关性肺炎及其他肺疾病中有一定疗效,因此可能是治疗COVID-19潜在有效药物。目前部分研究也显示出积极的治疗效果,而具体的疗效仍需进一步的临床研究来验证。

COVID-19 is caused by novel coronavirus(SARS-CoV-2),which can lead to severe lung injury and even death.SARS-CoV-2 infection induces immune disorders in the body,leading to cytokine storm and targeted organ damages via the angiotensin converting enzyme 2(ACE2)and transmembrane protease serine 2.There are still no specific drugs for COVID-19.Mesenchymal stem cells(MSCs)have many functions,such as tissue repair,immune regulation,etc.They have certain therapeutic effects on influenza virus-associated pneumonia and other lung diseases,and are expected to become an effective drug for the treatment of COVID-19.At present,some studies have shown its positive therapeutic effects,but its specific efficacy remains to be confirmed by further clinical studies.